Antiviral Agents EyeDrops Sales

Antiviral Agents EyeDrops Sales Market Outlook

The global market for antiviral agents used in eye drops is poised for significant growth, projected to reach approximately USD 1.5 billion by 2035, with a compound annual growth rate (CAGR) of around 6.5% during the forecast period of 2025 to 2035. This growth can be attributed to the increasing prevalence of viral eye infections, rising awareness regarding eye health, and advancements in ophthalmic formulations. Moreover, the recent surge in the number of patients suffering from conditions such as viral conjunctivitis and herpetic keratitis has accelerated the demand for effective antiviral treatments. Innovations in drug delivery systems are also enhancing the effectiveness of these eye drops, leading to improved patient outcomes and greater adoption by healthcare professionals.

Growth Factor of the Market

The growth factors driving the antiviral agents eye drops market are multifaceted and complex, with several trends playing a crucial role in shaping the landscape. Firstly, the rising incidence of viral eye diseases, particularly among aging populations, is a primary catalyst for market expansion. As individuals age, they become more susceptible to infections, thereby increasing the demand for efficient therapeutic solutions. Additionally, the growing awareness about eye health, fortified by educational campaigns and digital health awareness, is propelling patients to seek out antiviral treatments more proactively. Furthermore, technological advancements in drug formulation and delivery methods, such as nanotechnology and sustained-release systems, are enhancing the therapeutic efficacy of eye drops, fostering greater patient adherence. The prevalence of chronic conditions that can lead to viral eye infections is also expected to drive the market forward, with healthcare providers increasingly recommending antiviral eye drops as part of comprehensive treatment plans.

Key Highlights of the Market

• The global antiviral agents eye drops market is projected to reach approximately USD 1.5 billion by 2035.
• North America is anticipated to hold the largest market share due to advanced healthcare infrastructure and high awareness levels.
• Technological advancements in drug formulations are expected to enhance product efficacy and patient compliance.
• The rising prevalence of viral conjunctivitis is a significant driver behind market growth.
• Over-the-counter (OTC) antiviral eye drops are gaining popularity, catering to the growing demand among consumers for self-medication options.

By Product Type

Prescription Antiviral Agents EyeDrops:

Prescription antiviral agents eye drops are formulated specifically for the treatment of viral infections that require medical supervision. These products typically contain potent active ingredients that target specific pathogens, ensuring effective treatment of conditions such as herpetic keratitis. The prescription segment has been gaining traction due to the increasing number of ocular viral infections and the necessity for specialized therapy. Healthcare providers are increasingly prescribing these agents, particularly as new formulations enter the market, offering improved efficacy and safety profiles. This segment is expected to witness steady growth as more patients seek professional medical advice for their eye health needs.

Over-the-Counter Antiviral Agents EyeDrops:

The over-the-counter (OTC) antiviral agents eye drops segment caters to consumers who prefer to manage their eye health independently without the need for a prescription. This segment has seen a surge in popularity due to the growing trend of self-medication and the increasing awareness about common viral eye conditions. OTC eye drops are typically formulated for the treatment of mild to moderate viral infections such as conjunctivitis and provide a convenient treatment option for patients. The accessibility of these products in pharmacies and online platforms enhances their appeal, contributing to the overall growth of this segment.

Herbal Antiviral Agents EyeDrops:

The herbal antiviral agents eye drops segment is gaining recognition among consumers seeking natural alternatives to conventional pharmaceutical treatments. These eye drops are formulated using plant-based ingredients known for their antiviral properties and are often preferred by those looking for gentler or holistic treatment options. The increasing trend towards herbal and organic products is fuelling the growth of this segment, as consumers are becoming more health-conscious and environmentally aware. Additionally, the rising interest in traditional medicine in various cultures supports the expansion of herbal formulations in the antiviral eye drop market.

Generic Antiviral Agents EyeDrops:

The generic antiviral agents eye drops segment is characterized by products that offer cost-effective alternatives to branded medications. As patents for leading antiviral formulations expire, generic versions enter the market, providing patients with more affordable options. This segment is particularly appealing to cost-sensitive consumers and healthcare systems looking to manage expenses while ensuring effective treatment. The increasing availability of generic antiviral agents is anticipated to foster competition, leading to improved pricing strategies and further expanding market reach.

Branded Antiviral Agents EyeDrops:

The branded antiviral agents eye drops segment remains a dominant force in the market, driven by the established reputation of well-known pharmaceutical companies. These products often come with extensive clinical validation and marketing support, reassuring healthcare professionals and patients of their efficacy and safety. Branded eye drops are typically associated with better patient adherence due to their established trust and recognition in the market. As innovation in formulation continues, this segment is expected to maintain its significance, with companies investing in research and development to introduce new and improved products.

By Application

Viral Conjunctivitis:

Viral conjunctivitis represents a leading application area for antiviral agents eye drops, as it is one of the most common viral eye infections affecting individuals worldwide. This condition, characterized by inflammation and redness of the conjunctiva, can spread easily, necessitating effective antiviral treatments to mitigate its impact. Antiviral eye drops specifically formulated for viral conjunctivitis help alleviate symptoms and reduce the duration of the infection. The increasing incidence of this condition, particularly in crowded environments such as schools and workplaces, is driving demand within this application segment significantly.

Herpetic Keratitis:

Herpetic keratitis is another critical application of antiviral agents eye drops, as it poses a significant risk of vision loss if not treated promptly. This condition, caused by the Herpes Simplex Virus, requires immediate medical intervention and specialized antiviral treatment to prevent corneal scarring and other complications. The rising prevalence of HSV infections, coupled with heightened awareness among healthcare professionals about the need for effective management strategies, has propelled demand for antiviral eye drops in this application segment. Continuous research and development aimed at improving treatment outcomes further bolster growth prospects.

Keratoconjunctivitis:

Keratoconjunctivitis, a condition characterized by inflammation of both the cornea and conjunctiva, often necessitates antiviral treatment, particularly when viral pathogens are involved. This application area is experiencing increased attention due to the potential for severe complications if left untreated. Antiviral eye drops are critical in managing symptoms and preventing progression of the disease. The growing incidence of viral infections and the expanding awareness of keratoconjunctivitis management strategies contribute to the overall growth of this segment, as healthcare providers seek effective antiviral solutions.

Others:

The "Others" category encompasses various less common applications of antiviral agents eye drops, including conditions such as viral uveitis and post-operative infections. Although these conditions are less prevalent, they require specialized antiviral treatments to ensure patient safety and optimize recovery outcomes. The expanding range of antiviral eye drop products is making it increasingly possible to address these niche applications effectively. As healthcare providers recognize the necessity for tailored antiviral solutions, this segment is expected to witness gradual growth, supported by ongoing research and advancements in ophthalmic therapies.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a pivotal role in the distribution of antiviral agents eye drops, providing essential medications to inpatients and outpatients alike. These pharmacies are often equipped with specialized knowledge regarding the usage of antiviral eye drops, enabling healthcare professionals to make informed recommendations. The high demand for prescription antiviral agents in hospitals, driven by the need for immediate treatment in acute cases, bolsters this distribution channel's growth. Moreover, partnerships between pharmaceutical companies and hospitals can enhance the availability of the latest antiviral formulations, ensuring that patients have access to cutting-edge treatments.

Online Pharmacies:

The online pharmacies segment has emerged as a significant distribution channel, reflecting the increasing trend towards e-commerce and convenience-driven shopping. Online platforms provide consumers with easy access to antiviral agents eye drops, often at competitive prices. The ability to compare products, read reviews, and receive medications discreetly has made online pharmacies a favored choice for many patients. Additionally, the COVID-19 pandemic has accelerated the adoption of online purchasing for healthcare products, further driving growth in this segment. As logistics and delivery systems improve, the online pharmacy channel is expected to expand significantly in the coming years.

Retail Pharmacies:

Retail pharmacies remain a crucial distribution channel for antiviral agents eye drops, offering a wide range of products directly to consumers. These pharmacies are often the first point of contact for individuals seeking treatment for viral eye infections, making them essential in the overall market landscape. The accessibility of antiviral eye drops in retail settings enhances patient convenience, allowing for prompt treatment initiation. Additionally, retail pharmacies frequently engage in promotional activities and patient education initiatives that raise awareness around viral eye conditions, further driving sales in this segment.

Drug Stores:

Drug stores contribute significantly to the distribution of antiviral agents eye drops, acting as a convenient source for patients seeking relief from viral eye infections. These establishments often carry a variety of both prescription and over-the-counter products, catering to diverse consumer preferences. The prevalence of drug stores in urban and suburban areas enhances accessibility for patients, facilitating timely treatment interventions. Drug stores also engage in community outreach and provide health-related advice, which can bolster the visibility and sales of antiviral eye drops.

Others:

The "Others" category incorporates various alternative distribution channels for antiviral agents eye drops, such as specialty pharmacies and clinics. Specialty pharmacies often focus on niche products and may provide tailored medication management services, making them valuable for patients with complex health conditions. Clinics that provide ophthalmic care may also distribute antiviral eye drops directly to patients, ensuring seamless access to necessary treatments. As more healthcare providers recognize the importance of a multi-channel distribution strategy, this segment is expected to witness growth driven by the diverse needs of patients and healthcare systems.

By Ingredient Type

Acyclovir:

Acyclovir is a widely used antiviral agent in eye drops, particularly effective against the Herpes Simplex Virus responsible for herpetic keratitis. Its efficacy in managing viral infections has positioned it as a primary ingredient in many formulations. Acyclovir works by inhibiting viral replication, thereby shortening the duration of the infection and alleviating symptoms. The increasing prevalence of herpetic infections is expected to drive demand for acyclovir-based eye drops in the market. Furthermore, ongoing research into enhanced formulations may lead to improved delivery systems that increase the agent's efficacy, further solidifying its market position.

Ganciclovir:

Ganciclovir is another critical ingredient found in antiviral agents eye drops, specifically indicated for treating cytomegalovirus (CMV) infections in the eye. Its powerful antiviral properties make it essential in the management of serious ocular infections. Ganciclovir eye drops are commonly prescribed in clinical settings, particularly for immunocompromised patients who are at a higher risk of viral infections. As awareness of CMV infections rises and the demand for effective treatments increases, ganciclovir-based eye drops are expected to see significant growth in market share.

Trifluridine:

Trifluridine is a potent antiviral agent utilized in eye drops primarily for the treatment of epithelial keratitis caused by the herpes simplex virus. Its unique mechanism of action allows it to inhibit viral DNA synthesis, making it an effective therapeutic option in managing viral ocular infections. Trifluridine's efficacy supports its continued use in clinical practice, with increased demand anticipated as more patients are diagnosed with viral keratitis. Continued research into optimizing its formulation and expanding its indications may enhance its presence in the market.

Cidofovir:

Cidofovir is a nucleotide analogue that has demonstrated efficacy against a variety of viral pathogens, including those responsible for serious ocular infections. Though not as widely used as some other antiviral agents, cidofovir eye drops are increasingly recognized for their potential in treating resistant viral infections. The ongoing investigation into its clinical applications and the development of more effective formulations may drive cidofovir's growth in the antiviral agents eye drops market, particularly in specialized and advanced treatment settings.

Tromantadine:

Tromantadine is an antiviral agent that has gained traction as an ingredient in eye drops, particularly in the treatment of viral conjunctivitis. Its unique properties allow it to inhibit viral replication while also exhibiting anti-inflammatory effects, making it a favorable option for managing symptoms of viral eye infections. The rising prevalence of conjunctivitis and the need for effective treatment options are likely to contribute to the growing popularity of tromantadine-based eye drops in the market. Furthermore, ongoing research into its effectiveness against various strains of viruses may enhance its application scope.

By Region

The North American region is anticipated to dominate the antiviral agents eye drops market, accounting for over 40% of the global revenue share by 2035. Key factors driving this growth include advanced healthcare infrastructure, high levels of awareness about eye health, and the presence of established pharmaceutical companies that invest in research and development. The increasing incidence of viral eye infections such as conjunctivitis and keratitis, coupled with the growing demand for effective treatment options, supports the region's growth trajectory. Additionally, the rise of telemedicine and online pharmacies is facilitating greater accessibility to antiviral agents, further propelling market expansion.

Europe is also expected to witness significant growth in the antiviral agents eye drops market, with a projected CAGR of 5.8% from 2025 to 2035. The region's increasing focus on patient-centered healthcare and the rising prevalence of viral eye infections are among the key factors contributing to this growth. Furthermore, the European market benefits from a robust regulatory framework that ensures the safety and efficacy of pharmaceutical products, thus fostering confidence among consumers. The emergence of innovative formulations and direct-to-consumer marketing strategies will likely enhance product visibility and stimulate demand in the European market.

Opportunities

The antiviral agents eye drops market presents numerous opportunities for growth and innovation, particularly in light of the increasing prevalence of viral eye infections. One significant opportunity lies in the development of next-generation formulations that can enhance patient compliance and treatment outcomes. By focusing on improving drug delivery systems, such as sustained-release formulations or combination therapies, pharmaceutical companies can create products that effectively address the needs of patients while minimizing the frequency of administration. Additionally, partnerships with healthcare providers for education and awareness initiatives can foster greater understanding of viral eye conditions, potentially expanding the user base for antiviral eye drops.

Another opportunity in the market is the increasing demand for herbal and natural-based antiviral eye drops, driven by the growing consumer trend towards holistic health and wellness. As more individuals seek alternatives to traditional pharmaceutical treatments, there is a significant opportunity for companies to develop and market effective herbal formulations. This trend aligns with the global movement towards sustainable and eco-friendly products, allowing brands to differentiate themselves through innovative and natural offerings. Investing in research to validate the efficacy of herbal ingredients can further enhance market growth and consumer trust.

Threats

Despite the promising growth outlook for the antiviral agents eye drops market, several threats could pose challenges to sustained market expansion. One of the primary threats is the rapid advancement of alternative treatment modalities, including antiviral oral medications and advanced delivery systems. These alternatives may overshadow the traditional eye drop formulations, particularly if they demonstrate superior efficacy or convenience. As patients become more informed about their options, there is a risk that the market for antiviral eye drops could diminish if companies do not innovate and differentiate their products effectively. Furthermore, stringent regulatory requirements and lengthy approval processes may hinder the introduction of new products, limiting the ability of manufacturers to respond swiftly to market demands.

In addition to alternative treatment modalities, the prevalence of counterfeit or substandard products in the market poses a significant threat to legitimate pharmaceutical companies. The sale of unapproved or ineffective antiviral eye drops could lead to negative health outcomes for patients, resulting in a loss of consumer trust and confidence in the market. As regulatory agencies strive to combat this issue, companies must invest in quality assurance and ensure compliance with established standards. Moreover, the rising cost of raw materials and potential supply chain disruptions could affect production capabilities, posing further challenges to market players.

Competitor Outlook

• Allergan, Inc.
• Novartis AG
• GlaxoSmithKline plc
• Bausch Health Companies Inc.
• Alcon Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca PLC
• UCB S.A.

The competitive landscape of the antiviral agents eye drops market is characterized by a diverse range of players, including well-established pharmaceutical companies and emerging firms focused on innovative solutions. Major companies in the market are leveraging their expertise in research and development to create advanced formulations that address the evolving needs of patients. Additionally, these companies are engaging in strategic partnerships and collaborations to enhance their product offerings and expand their market presence. As competition intensifies, companies are prioritizing their marketing efforts to effectively communicate the benefits of their products and capture the attention of healthcare professionals and end-users alike.

Allergan, Inc. is recognized as a prominent player in the antiviral agents eye drops market, particularly due to its well-established product portfolio and strong presence in the ophthalmic sector. The company invests significantly in clinical research to develop innovative solutions for viral eye infections, positioning itself as a trusted brand among healthcare providers and patients. Novartis AG also stands out in the market, emphasizing its commitment to researching new therapies for ocular diseases and investing in the development of effective antiviral formulations. The company's strong global presence and established distribution networks enable it to reach a wide customer base, thus bolstering its competitive advantage.

Other key players such as GlaxoSmithKline and Bausch Health Companies are focusing on expanding their portfolios through research and product development activities. GlaxoSmithKline, with its extensive history in eye care, is dedicated to exploring new treatment options and addressing unmet medical needs in the antiviral eye drops market. Meanwhile, Bausch Health's commitment to innovation and quality assurance has garnered it a loyal customer base, further enhancing its market position. As the market evolves, these companies continue to adapt to changing consumer preferences and market dynamics, ensuring they remain competitive in the antiviral agents eye drops sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Alcon Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca PLC
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 GlaxoSmithKline plc
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals PLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bausch Health Companies Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Otsuka Pharmaceutical Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Santen Pharmaceutical Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Antiviral Agents EyeDrops Sales Market, By Application
    • 6.1.1 Viral Conjunctivitis
    • 6.1.2 Herpetic Keratitis
    • 6.1.3 Keratoconjunctivitis
    • 6.1.4 Others
  • 6.2 Antiviral Agents EyeDrops Sales Market, By Product Type
    • 6.2.1 Prescription Antiviral Agents EyeDrops
    • 6.2.2 Over-the-Counter Antiviral Agents EyeDrops
    • 6.2.3 Herbal Antiviral Agents EyeDrops
    • 6.2.4 Generic Antiviral Agents EyeDrops
    • 6.2.5 Branded Antiviral Agents EyeDrops
  • 6.3 Antiviral Agents EyeDrops Sales Market, By Ingredient Type
    • 6.3.1 Acyclovir
    • 6.3.2 Ganciclovir
    • 6.3.3 Trifluridine
    • 6.3.4 Cidofovir
    • 6.3.5 Tromantadine
  • 6.4 Antiviral Agents EyeDrops Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Online Pharmacies
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Antiviral Agents EyeDrops Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Antiviral Agents EyeDrops Sales market is categorized based on

By Product Type

• Prescription Antiviral Agents EyeDrops
• Over-the-Counter Antiviral Agents EyeDrops
• Herbal Antiviral Agents EyeDrops
• Generic Antiviral Agents EyeDrops
• Branded Antiviral Agents EyeDrops

By Application

• Viral Conjunctivitis
• Herpetic Keratitis
• Keratoconjunctivitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Acyclovir
• Ganciclovir
• Trifluridine
• Cidofovir
• Tromantadine

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan, Inc.
• Novartis AG
• GlaxoSmithKline plc
• Bausch Health Companies Inc.
• Alcon Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Santen Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca PLC
• UCB S.A.